Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells

  title={Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells},
  author={Elisa Giovannetti and Valentina Mey and Sara Nannizzi and Giuseppe Pasqualetti and Luca Marini and Mario del Tacca and Romano Danesi},
  journal={Molecular Pharmacology},
  pages={110 - 118}
Gemcitabine and pemetrexed are effective agents in the treatment of non–small-cell lung cancer (NSCLC), and the present study investigates cellular and genetic aspects of their interaction against A549, Calu-1, and Calu-6 cells. Cells were treated with pemetrexed and gemcitabine, and their interaction was assessed using the combination index. The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5′-nucleotidase, and cytidine… 

Figures and Tables from this paper

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
Evidence is provided that the chemotherapeutic activity of the combination of gem citabine and pemetrexed is synergistic against bladder cancer cells in vitro and that the assessment of the expression of genes involved in gemcitabine uptake and activation might be a possible determinant of bladder cancer response and may represent a new tool for treatment optimization.
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
It is demonstrated that oxaliplatin and pemetrexed synergistically interact against colon cancer cells, through modulation of cell cycle, inhibition of Akt phosphorylation, induction of apoptosis and modulation of gene expression.
Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
The effects of enzastaurin on signaling pathways involved in cell cycle control, apoptosis and angiogenesis, as well as on the expression of genes involved in pemetrexed activity provide a strong experimental basis to their evaluation as pharmacodynamic markers in clinical trials of enzastsaurin-pemetrexe combination in NSCLC patients.
Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach
  • T. De Pas, F. Toffalorio, F. D. De Braud
  • Biology, Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2011
This is the first evidence of dCK and hENT1 induction by pemetrexed in humans, suggesting that the pemet Rexed→gemcitabine combination should be optimized by the administration of gemcitabines 1 to 2 or 24 to 48 hours after pemetrezed.
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
The results from the phase III upfront registration study, a retrospective observational data, and a recent maintenance study of pemetrexed in NSCLC suggest histological subtype to be the most important predictive marker for clinical outcome in patients receiving pemetrixed.
Schedule-Dependent Synergistic Effect of Pemetrexed Combined with Gemcitabine against Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer Cell Lines
Sequential administration of MTA and G EM is active, and the schedule of MTA followed by GEM is recommended for treating MPM.
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
The combination of fluvastatin and gemcitabine is an effective cytotoxic, proapoptotic treatment in vitro and in vivo against MIAPaCa-2 cells by a mechanism of action mediated, at least in part, by the inhibition of p21ras and rhoA prenylation.
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells Fast
Evaluating molecular mechanisms underlying the synergistic between erlotinib and the antimetabolite pemetrexed through the in vitro assessment of pathway may modulate the effects of the erlotine-kinase inhibitor-pemetrexe combination found that EGFR and k-Ras mutations were related to erlot inib sensitivity, while TS and DHFR expression was related to pemet Rexed sensitivity.
Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells
Erlotinib and pemetrexed showed a strong synergism in NSCLC cells, regardless of their genetic characteristics, and these mechanisms support the clinical investigation of these markers.


Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines
It is demonstrated that the gemcitabine and pemetrexed combination displays schedule-dependent synergistic cytotoxic activity, favorably modulates cell cycle, induces apoptosis, and enhances dCK expression in pancreatic cancer cells.
Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines
In vitro modeling of gem citabine and carboplatin as well as gemcitabine/carboplatin and paclitaxel demonstrates synergistic interaction regardless of p16, p53, or Rb status.
In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
The results indicate that the sequential administration of GEM --> MTA provides the greatest benefit in the clinical treatment of colon cancer.
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
The synergism between dFdC and CDDP appears to be mainly due to an increase in Pt–DNA adduct formation possibly related to changes in DNA due to dFDC incorporation into DNA.
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.
The data suggested that the type of NT activities possessed by a cell may be an important determinant of its sensitivity to gem citabine and that NT deficiency may confer significant gemcitabine resistance.
Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis
The results demonstrate that the distinct endpoints of GARFT and TS inhibition are preceded by distinct cell cycle and metabolic alterations.
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Gemcitabine monotherapy produced an objective tumour response in 18 to 26% of patients with advanced non-small cell lung cancer (NSCLC) and appears to have similar efficacy to cisplatin plus etoposide and may be cost effective compared with best supportive care for NSCLC.
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Modulation of the es-NT by pretreatment with TS inhibitors may have the potential to improve the therapeutic benefit of gemcitabine.